- Innovate (NYSE:VATE) announced today that the U.S. Food and Drug Administration has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function.
- The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones.
